Literature DB >> 32439504

Serum IgG Levels and Risk of COPD Hospitalization: A Pooled Meta-analysis.

Fernando Sergio Leitao Filho1, Andre Mattman2, Robert Schellenberg1, Gerard J Criner3, Prescott Woodruff4, Stephen C Lazarus4, Richard K Albert5, John Connett6, Meilan K Han7, Steven E Gay7, Fernando J Martinez8, Anne L Fuhlbrigge9, James K Stoller10, Neil R MacIntyre11, Richard Casaburi12, Philip Diaz13, Ralph J Panos14, J Allen Cooper15, William C Bailey16, David C LaFon16, Frank C Sciurba17, Richard E Kanner18, Roger D Yusen19, David H Au20, Kenneth C Pike20, Vincent S Fan21, Janice M Leung1, Shu-Fan Paul Man1, Shawn D Aaron22, Robert M Reed23, Don D Sin24.   

Abstract

BACKGROUND: Hypogammaglobulinemia (serum IgG levels < 7.0 g/L) has been associated with increased risk of COPD exacerbations but has not yet been shown to predict hospitalizations. RESEARCH QUESTION: To determine the relationship between hypogammaglobulinemia and the risk of hospitalization in patients with COPD. STUDY DESIGN AND METHODS: Serum IgG levels were measured on baseline samples from four COPD cohorts (n = 2,259): Azithromycin for Prevention of AECOPD (MACRO, n = 976); Simvastatin in the Prevention of AECOPD (STATCOPE, n = 653), Long-Term Oxygen Treatment Trial (LOTT, n = 354), and COPD Activity: Serotonin Transporter, Cytokines and Depression (CASCADE, n = 276). IgG levels were determined by immunonephelometry (MACRO; STATCOPE) or mass spectrometry (LOTT; CASCADE). The effect of hypogammaglobulinemia on COPD hospitalization risk was evaluated using cumulative incidence functions for this outcome and deaths (competing risk). Fine-Gray models were performed to obtain adjusted subdistribution hazard ratios (SHR) related to IgG levels for each study and then combined using a meta-analysis. Rates of COPD hospitalizations per person-year were compared according to IgG status.
RESULTS: The overall frequency of hypogammaglobulinemia was 28.4%. Higher incidence estimates of COPD hospitalizations were observed among participants with low IgG levels compared with those with normal levels (Gray's test, P < .001); pooled SHR (meta-analysis) was 1.29 (95% CI, 1.06-1.56, P = .01). Among patients with prior COPD admissions (n = 757), the pooled SHR increased to 1.58 (95% CI, 1.20-2.07, P < .01). The risk of COPD admissions, however, was similar between IgG groups in patients with no prior hospitalizations: pooled SHR = 1.15 (95% CI, 0.86-1.52, P =.34). The hypogammaglobulinemia group also showed significantly higher rates of COPD hospitalizations per person-year: 0.48 ± 2.01 vs 0.29 ± 0.83, P < .001.
INTERPRETATION: Hypogammaglobulinemia is associated with a higher risk of COPD hospital admissions.
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COPD; hospitalizations; hypogammaglobulinemia; immunoglobulin G; meta-analysis

Mesh:

Substances:

Year:  2020        PMID: 32439504     DOI: 10.1016/j.chest.2020.04.058

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study.

Authors:  Samer R Khan; Anna Vanoverschelde; Lies Lahousse; Robin P Peeters; P Martin van Hagen; Guy Brusselle; Layal Chaker; Virgil A S H Dalm
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

2.  The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD.

Authors:  Hyun Lee; Cara Kovacs; Andre Mattman; Zsuzsanna Hollander; Virginia Chen; Raymond Ng; Janice M Leung; Don D Sin
Journal:  Respir Res       Date:  2022-05-31

3.  Specific Antibody Deficiency in Adult Patients With IgG or IgG Subclass Deficiency.

Authors:  Joo Hee Kim; Jae Hyuk Jang; So Hee Lee; Eun Mi Yang; Seung Hun Jang; Ki Suck Jung; Hae Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2021-03       Impact factor: 5.764

4.  Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial.

Authors:  Severin Vogt; Jörg D Leuppi; Jonas Rutishauser; Michael Osthoff; Philipp Schuetz; Beat Mueller; Carmen Volken; Sarah Dräger; Marten Trendelenburg
Journal:  Respir Res       Date:  2021-08-14

Review 5.  Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?

Authors:  Jennifer M Wang; MeiLan K Han; Wassim W Labaki
Journal:  Curr Opin Pulm Med       Date:  2022-03-01       Impact factor: 3.155

6.  A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD.

Authors:  Juthaporn Cowan; Sunita Mulpuru; Sara J Abdallah; Anchal Chopra; Andrew Purssell; Michaeline McGuinty; Gonzalo G Alvarez; Antonio Giulivi; Vicente Corrales-Medina; Derek MacFadden; Loree Boyle; Delvina Hasimja; Kednapa Thavorn; Ranjeeta Mallick; Shawn D Aaron; D William Cameron
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-03

7.  Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease.

Authors:  Ana I Hernández Cordero; Chen Xi Yang; Xuan Li; Stephen Milne; Virginia Chen; Zsuzsanna Hollander; Raymond Ng; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; John E Connett; MeiLan K Han; Fernando J Martinez; Robert M Reed; S F Paul Man; Janice M Leung; Don D Sin
Journal:  Respir Res       Date:  2021-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.